First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study – FRONTIERS IN ONCOLOGY

Piedra, A; Martínez-Recio, S; Hernández, A; Morán, T; Arriola, E; Recuero-Borau, J; Cobo, M; Cordeiro, P; Mosquera, J; Fernández, M; García-Campelo, R; Calles, A; Alvarez, R; Zapata-García, M; Isla, D; Callejo, A; Iranzo, P; Serra-López, J; Barba, A; Sullivan, I; Felip, E; Majem, M – 2024 – 10.3389/fonc.2024.1510278